RBC Capital Maintains Outperform on Caribou Biosciences, Lowers Price Target to $19
RBC Capital analyst Luca Issi maintains Caribou Biosciences (NASDAQ:CRBU) with a Outperform and lowers the price target from $22 to $19.
Recap: Caribou Biosciences Q2 Earnings
Caribou Biosciences (NASDAQ:CRBU) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Analysts Remain Bullish Despite Caribou’s Allogeneic CAR-T Hit By Durability
Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in…
70 Stocks Moving In Monday’s Mid-Day Session
Gainers
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday.
What’s Going On With Caribou Biosciences Shares Today?
Caribou Biosciences, Inc. (NASDAQ: CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.